Quest Laboratories Ltd
Incorporated in 1998, Quest Laboratories Ltd is a pharmaceutical manufacturer specializing in diverse therapeutic segments[1]
- Market Cap ₹ 179 Cr.
- Current Price ₹ 109
- High / Low ₹ 197 / 85.1
- Stock P/E 15.2
- Book Value ₹ 48.7
- Dividend Yield 0.00 %
- ROCE 57.5 %
- ROE 46.1 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 45.5%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 46.3 days to 73.8 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|
| 30 | 59 | 62 | 83 | 84 | |
| 29 | 53 | 54 | 67 | 67 | |
| Operating Profit | 1 | 6 | 8 | 16 | 18 |
| OPM % | 5% | 11% | 13% | 19% | 21% |
| 0 | 0 | 0 | 0 | 1 | |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 1 | 6 | 7 | 14 | 17 |
| Tax % | 18% | 29% | 28% | 30% | |
| 1 | 4 | 5 | 10 | 12 | |
| EPS in Rs | 8.45 | 8.05 | |||
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 40% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 148% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 45% |
| Last Year: | 46% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 | 16 |
| Reserves | 5 | 9 | 14 | 17 | 63 |
| 3 | 3 | 4 | 5 | 10 | |
| 9 | 22 | 28 | 26 | 23 | |
| Total Liabilities | 18 | 35 | 47 | 59 | 113 |
| 6 | 7 | 10 | 10 | 11 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 12 | 27 | 37 | 49 | 101 | |
| Total Assets | 18 | 35 | 47 | 59 | 113 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 1 | 3 | 4 | 3 | |
| -1 | -2 | -4 | -5 | |
| 0 | -0 | 0 | 2 | |
| Net Cash Flow | -0 | 1 | 0 | 0 |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 110 | 135 | 118 | 104 |
| Inventory Days | 12 | 9 | 97 | 113 |
| Days Payable | 119 | 140 | 215 | 137 |
| Cash Conversion Cycle | 3 | 4 | 1 | 79 |
| Working Capital Days | 31 | 25 | 40 | 74 |
| ROCE % | 55% | 47% | 58% |
Documents
Announcements
-
General Updates
11 March 2025 - Quest Laboratories Limited has informed about General Updates
-
Analysts/Institutional Investor Meet/Con. Call Updates
6 March 2025 - Quest Laboratories Limited has informed about INVESTOR MEET CANCELLED
-
Analysts/Institutional Investor Meet/Con. Call Updates
27 February 2025 - Quest Laboratories Limited has informed about Schedule of meet
-
General Updates
18 February 2025 - Quest Laboratories Limited has informed about General Updates
-
Analysts/Institutional Investor Meet/Con. Call Updates
14 February 2025 - Quest Laboratories Limited has informed about OUTCOME
Annual reports
Concalls
-
Dec 2024TranscriptNotesPPT
Business Overview:[1][2]
a) QLL specializes in manufacturing a wide range of pharmaceutical formulations, including antibiotics, antimalarials, anti-inflammatories, respiratory medications,
diabetes treatments, and more.
b) Company also produces a wide range of ethical, generic, and over-the-counter (OTC) drugs in various forms, including tablets, liquids, oral powders, ORS, ointments, and external liquids.
c) Quest offers facilities for institutional supplies, domestic ethical products, PCD, Contract manufacturing, and export, with
a focus on a wide range of specialized formulations and molecules
d) The company has 800+ Licensed Formulations, 272+ Active Products, 25cr.+Order Book from Myanmar